2-([1,2,4]Oxadiazol-3-ylmethylsulfanyl)-5-thiophen-2-ylmethyl-pyrimidin-4-ylamine | 476302-13-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-([1,2,4]Oxadiazol-3-ylmethylsulfanyl)-5-thiophen-2-ylmethyl-pyrimidin-4-ylamine
• 英文别名: 2-(1,2,4-Oxadiazol-3-ylmethylsulfanyl)-5-(thiophen-2-ylmethyl)pyrimidin-4-amine
• CAS: 476302-13-3
• 化学式: C₁₂H₁₁N₅OS₂
• 分子量: 305.384
• InChiKey: PSZMOOBUQRIWQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  144
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• 4-aminopyrimidine derivatives
  申请人：——

  公开号：US20030022907A1

  公开（公告）日：2003-01-30

  This invention is 4-aminopyrimidine derivatives of the formula 1 wherein R 1 , R 2 , R 3 and R 4 are as defined in the specification or a pharmaceutically acceptable salt thereof. The invention also is the preparation of compounds of formula I, pharmaceutical compositions containing therapeutically effective amounts of compounds of formula I or pharmaceutically acceptable salts thereof and to a method of treatment comprising administering therapeutically effective amounts of the compound of formula I for the prevention or treatment of mGluR5 receptor mediated disorders.

  这项发明是公式1中的4-氨基嘧啶衍生物，其中R1、R2、R3和R4如规范中定义或其药用可接受盐。该发明还涉及制备公式I化合物，含有公式I化合物的药物组合物，或其药用可接受盐的治疗有效量，并涉及一种治疗方法，包括给予公式I化合物的治疗有效量以预防或治疗mGluR5受体介导的疾病。
• 4-AMINOPYRIMIDINE DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1395568B1

  公开（公告）日：2006-11-02
• US7138404B2
  申请人：——

  公开号：US7138404B2

  公开（公告）日：2006-11-21
• [EN] 4-AMINOPYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE 4-AMINOPYRIMIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002094795A1

  公开（公告）日：2002-11-28

  This invention relates to 4-aminopyrimidine derivatives of the general formula (I) wherein R?1, R2, R3 and R4¿ have the signifiances defined in the specification and their pharmaceutically acceptable salts. The invention further relates to the preparation of such compounds, to medicaments containing such compounds and to their use for the prevention or treatment of mGluR5 receptor mediated disorders.